site stats

Ceptaris therapeutics

WebCeptaris Therapeutics, Inc. Feb 2011 - Mar 2013 2 years 2 months. Greater Philadelphia Area Led global registration of oncology product Shire 9 years VP & General Manager, … WebFeb 21, 2012 · Ceptaris Therapeutics Inc is a privately held specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine …

EIN 23-2186884 - Vanguard Fiduciary Trust Co, Malvern, …

WebCeptaris Therapeutics, Inc. Developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of … WebJul 31, 2013 · Ceptaris Therapeutics Inc. is a privately held, specialty pharmaceutical company that was established to develop a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of ... design your own wrestling shoes https://quiboloy.com

Stephen Tullman, Chairman & CEO, Ceptaris Therapeutics - Topio …

WebManufactured for: Ceptaris Therapeutics, Inc., Malvern, PA 19355 © 2013 Ceptaris Therapeutics, Inc. All rights reserved. For more information, go to … WebStephen Tullman is Board member at Velicept Therapeutics. Tullman hass more than 23 years of biopharmaceutical global commercialization and drug development experience. … WebHer biotech career started with Ception Therapeutics as a Senior Accountant. Following Ception, she owned and operated her own accounting business, DanJenn, Inc. where she continued to work for various start-up biotech companies (Ceptaris Therapeutics, Inc., Velicept Therapeutics, Inc. and Onspira Therapeutics, Inc.) on a consulting basis. design your own wreath

Ceptaris BioAdvance

Category:Actelion enters into an agreement to acquire privately-held Ceptaris ...

Tags:Ceptaris therapeutics

Ceptaris therapeutics

Johnson & Johnson Profile: Summary • OpenSecrets

WebRepresented Ceptaris Therapeutics in its acquisition by Actelion (Switzerland) for $250 million cash plus undisclosed milestone payments and sales earnouts. Represented a French CAC 40 company in connection with the sale … WebFeb 21, 2024 · Chief Medical Officer at Avalo Therapeutics "Dr. H. Jeffrey Wilkins is chief medical officer of Lycera. Dr. Wilkins brings over 15 years of clinical research experience, most recently serving as Clinical Lead and Partner of NeXeption, LLC, a biopharmaceutical management company. Previously, he was Chief Medical Officer and Head of Medical …

Ceptaris therapeutics

Did you know?

WebTo report SUSPECTED ADVERSE REACTIONS, contact Ceptaris Therapeutics, Inc. at 1‐855‐4‐VALCHLOR (1‐855‐482‐5245) or FDA at 1‐800‐FDA‐1088 or … WebCeptaris Therapeutics has 5 current employee profiles, including Vice President of Project Management and Operations Jeffrey Shaver. Jeffrey Shaver Vice President of Project Management and Operations. John N. Irwin Co-Founder. Tim Henkel Executive Vice President, Head of Research and Development. Doug Gessl COO & CFO.

WebJul 31, 2013 · Actelion Pharmaceuticals Ltd / Actelion enters into an agreement to acquire privately-held Ceptaris Therapeutics . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible... April 5, 2024 WebCeptaris Therapeutics, Inc. was subsequently acquired by Swiss based Actelion Ltd for over $250 MM and additional payments. Nonclinical …

WebJan 1, 2015 · Henkel was also Executive Vice President of Research and Development at Ception Therapeutics (acquired by Cephalon), Executive Vice President and Chief … WebDoing Business As: Ceptaris Therapeutics Inc Phone: 610-975-9290. Benten Bioservices, Inc. EIN Number: 02-0806340 Address: 347 Phoenixville Pike, Malvern, Pennsylvania, 19355 Doing Business As: Benten Bioservices Inc Phone: 610-854-4700. Phasebio Pharmaceuticals Inc. EIN Number: 03-0375697

WebAug 26, 2013 · Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that has developed a proprietary gel formulation of mechlorethamine …

WebAug 1, 2013 · Date with density. The deal will see Actelion pay an additional $225m to acquire Pennsylvania-based Ceptaris on FDA approval of Valchlor, once known as Clearazide, and pending certain other undisclosed conditions. Formerly known as Yaupon Therapeutics, Ceptaris is on its second attempt to get the proprietary gel formulation of … design your own xboxWebFeb 21, 2012 · Ceptaris Therapeutics, Inc., a Malvern, PA-based specialty pharmaceutical company, secured $15m in venture debt financing from Silicon Valley Bank and Oxford Finance. Led by President and CEO ... chucking forkWebActelion Ltd. in its acquisition of Ceptaris Therapeutics for $250 million upfront and additional royalty and potential milestone payments. Eisai Inc. in its divestiture of US rights to Gliadel® Wafer to Arbor Pharmaceuticals. Numerous emerging and leading biopharmaceutical, diagnostic and medical device companies in the U.S. rollout of Phase ... chucking cricketWebCeptaris developed VALCHLOR™, a proprietary gel formulation of mechlorethamine for the treatment of early stage (IA and IB) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL). VALCHLOR was the first FDA-approved topical mechlorethamine product available to treat the signs and symptoms of this rare cancer. ... TerSera Therapeutics ... chucking friction massageWebMost recently Mr Alonso successfully founded Ceptaris Therapeutics, where he raised over $40 million in venture capital, steered the lead program through phase III testing and filing of an NDA (Approval was received in 2013). Ceptaris was sold in 2013 to Actellion Pharmaceuticals. Mr. Alonso is a seasoned executive who has completed numerous ... design your own zippoWebJun 5, 2012 · Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine … design your own yoga mat australiaWebCeptaris Therapeutics, Inc. produces and distributes pharmaceutical products. The Company offers prescription medications for the treatment of mycosis fungoides type of … design your own xbox one